Investors/Media

September 7, 2021
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 7, 2021-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will
August 11, 2021
Presentations from Spruce leadership team & KOL panel discussion featuring Richard Auchus, MD, PhD and Paul Thornton, MD San Francisco, Calif. – August 11, 2021 – Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel
Displaying 1 - 10 of 14